In this context, a phase I clinical trial demonstrated that a single infusion injection of rhLCAT (ACP-501) had an acceptable safety profile and favorably altered HDL metabolism, showing a dose-proportional increase in HDL-C, thus supporting the investigation of this therapy in individuals with atherosclerotic disease and LCAT deficiency (118). This evidence concerns the gene LCAT and hyperinsulinemic hypoglycemia, familial, 4.